Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

548
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
548
Antibody Structure01:10

Antibody Structure

59.6K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.6K
Affinity and Avidity01:41

Affinity and Avidity

35.9K
Overview
35.9K
Antibody Structure and Classes01:25

Antibody Structure and Classes

859
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
859
Hybridoma Technology01:31

Hybridoma Technology

14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Decoupled carbon assimilation and growth responses to aridity in temperate deciduous oaks.

Science advances·2026
Same author

Outcomes of Total Hip Arthroplasty Based on Surgeon Fellowship and Case Volume.

The Journal of arthroplasty·2026
Same author

A Propensity-Matched Analysis of the Impact of Sternal Fractures on Outcomes in Concurrent Thoracic Spine Fractures: The Fourth Column of the Spine.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same author

Management of Anterior Glenohumeral Dislocations in Elderly Patients.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same author

Tree defenses, host choice, and reproductive success of a native bark beetle under novel outbreak conditions.

Ecological applications : a publication of the Ecological Society of America·2026
Same author

Digital Solutions in HF Education: What Can Patients and Clinicians Gain?

Current heart failure reports·2026

相关实验视频

Updated: Jun 15, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K

对双特异性和多特异性抗体的可开发性考虑.

Alaa Amash1, Gesa Volkers1, Patrick Farber1

  • 1AbCellera Biologics Inc, Vancouver, BC, Canada.

mAbs
|August 27, 2024
PubMed
概括

开发双特异性 (bsAb) 和多特异性 (msAb) 抗体需要早期开发能力评估. 本指南提供了评估这些复杂生物制剂的策略,以确保治疗潜力和成功的临床开发.

关键词:
抗体是对抗体的一种.两种类型的两种类型的两种类型开发能力 开发能力格式 格式 格式 格式免疫性 免疫性 免疫性可以制造的可制造性.多种多样性的多种类型.特殊性的特异性稳定的稳定性 稳定的稳定性

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K

相关实验视频

Last Updated: Jun 15, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K

科学领域:

  • 生物技术和制药科学 生物技术和制药科学
  • 免疫学和分子生物学

背景情况:

  • 双特异性抗体 (bsAb) 和多特异性抗体 (msAb) 通过同时向多个表位体,提供了新的治疗策略.
  • 这些先进的生物药物有望治疗具有挑战性的和以前无法治愈的疾病.
  • 有效的开发需要在管道的早期严格评估抗体开发能力.

研究的目的:

  • 总结对双特异性和多特异性抗体的开发性评估的关键方面.
  • 为制定针对特定的bsAb/msAb格式量身定制的全面可开发性评估计划提供指导.
  • 为了方便选择有前途的抗体候选人进行进一步开发.

主要方法:

  • 对评估基于蛋白质的治疗开发能力的既定和新兴方法的审查.
  • 确定bsAbs/msAbs特定的关键可开发性考虑因素,包括格式,免疫性,特异性,稳定性和生产.
  • 为全面的开发能力评估制定战略框架.

主要成果:

  • 目前用于开发能力评估的方法往往没有对复杂的bsAbs/msAbs进行验证.
  • 影响bsAb/msAb开发能力的关键因素包括分子格式,免疫性,特异性,稳定性和生产可扩展性.
  • 结构化的方法对于评估这些先进治疗方式的潜力至关重要.

结论:

  • 早期和彻底的开发能力评估对于推进双特异性和多特异性抗体至关重要.
  • 需要一个量身定制的,强大的评估计划来应对bsAb/msAb开发的独特挑战.
  • 这种战略方法支持有前途的抗体候选人的临床应用的成功进展.